GlassScriptPhysician profile
Jie Yang
NPI 1386719060
$18,059.72
in general payments reported to CMS, 2019-2025
79 companies · $3,542 in 2025
The $3,542 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $1,303 · 2021: $2,087 · 2022: $2,735 · 2023: $2,855 · 2024: $3,452 · 2025: $3,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,334 · Long Term Medical Supply Or Device Loan: $299 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,334.09 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $215.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,584.08 | 2019-2025 | |
| Janssen Biotech, INC. | $1,373.46 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Astrazeneca Pharmaceuticals LP | $1,082.44 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Pfizer INC. | $1,052.18 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $861.81 | 2019-2025 | |
| Genzyme Corporation | $689.77 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $642.03 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Incyte Corporation | $621.43 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $616.77 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Merck Sharp & Dohme LLC | $598.17 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Celgene Corporation | $556.68 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $407.36 | 2019-2025 | Tecentriq, Venclexta, Alecensa |
| Eisai INC. | $399.35 | 2019-2025 | |
| Seagen INC. | $398.29 | 2019-2024 | Adcetris, Tukysa, Padcev |
| Lilly USA, LLC | $395.51 | 2019-2024 | Verzenio |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $382.84 | 2019-2025 | Trodelvy |
| Abbvie INC. | $357.38 | 2019-2025 | Venclexta |
| Exelixis INC. | $328.95 | 2019-2025 | Cabometyx |
| Janssen Pharmaceuticals, INC | $312.44 | 2019-2023 | Xarelto |
| Ipsen Biopharmaceuticals, INC | $297.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.93 | 2020-2025 | Ninlaro, Alunbrig |
| Amgen INC. | $274.30 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| E.R. Squibb & Sons, L.L.C. | $258.56 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Glaxosmithkline, LLC. | $252.21 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Jazz Pharmaceuticals INC. | $238.58 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $200.70 | 2019-2025 | Ultomiris |
| Epizyme, INC. | $197.33 | 2021-2022 | |
| Array Biopharma INC | $193.24 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Adc Therapeutics America, INC. | $190.58 | 2022-2025 | |
| Blueprint Medicines Corporation | $182.66 | 2023-2024 | Ayvakit |
| Mirati Therapeutics, INC. | $174.88 | 2023-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $174.86 | 2021-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $167.69 | 2021-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $167.03 | 2021-2025 | Libtayo |
| Sobi, INC | $161.73 | 2022-2025 | |
| Daiichi Sankyo INC. | $159.16 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Sumitomo Pharma America, INC. | $135.14 | 2023-2025 | Orgovyx |
| Pharmaessentia USA Corporation | $109.87 | 2022-2025 | Besremi |
| Geron Corporation | $101.70 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $101.45 | 2021-2024 | Fotivda |
| Emd Serono, INC. | $94.61 | 2019-2025 | Bavencio |
| Stemline Therapeutics INC. | $93.44 | 2023-2025 | Orserdu, Elzonris |
| Pharmacosmos Therapeutics INC. | $90.24 | 2021-2024 | Cosela |
| Coherus Oncology, INC. | $68.42 | 2020-2025 | Loqtorzi |
| Amag Pharmaceuticals, INC. | $66.90 | 2019-2022 | |
| Kite Pharma, INC. | $64.04 | 2020-2024 | Yescarta |
| Taiho Oncology, INC. | $63.71 | 2019-2025 | |
| Beone Medicines USA, INC. | $61.22 | 2025 | Brukinsa, Tevimbra |
| Morphosys, US INC. | $57.39 | 2022-2023 | Monjuvi |
| Servier Pharmaceuticals LLC | $50.42 | 2025 | |
| Beigene USA, INC. | $47.46 | 2020-2021 | |
| Dova Pharmaceuticals | $46.46 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $45.58 | 2022 | |
| Iovance Biotherapeutics, INC. | $44.56 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $39.93 | 2021-2024 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $34.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.32 | 2019 | |
| Tersera Therapeutics LLC | $31.23 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $26.13 | 2019 | |
| Verastem, INC. | $24.22 | 2025 | Avmapki Fakzynja Co-Pack |
| Csl Behring | $23.06 | 2019 | |
| Agios Pharmaceuticals, INC. | $22.11 | 2025 | Pyrukynd |
| Myovant Sciences INC. | $20.99 | 2021 | |
| Kyowa Kirin, INC. | $20.78 | 2019 | |
| Cti Biopharma Corp. | $19.84 | 2023 | Vonjo |
| Advanced Accelerator Applications | $19.06 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.02 | 2025 | Danziten |
| Recordati_rare_diseases_inc. | $18.74 | 2025 | Enjaymo |
| Foundation Medicine, INC. | $18.58 | 2022 | |
| Fortovia Therapeutics, INC. | $17.43 | 2019 | |
| Heron Therapeutics, INC. | $16.92 | 2021 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Clovis Oncology, INC. | $15.07 | 2019 | |
| Shire North American Group INC | $12.96 | 2019 | |
| Sirtex Medical INC | $11.29 | 2023 | Sir-Spheres Microspheres |
| Ferring Pharmaceuticals INC. | $11.11 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$500.05 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.